TRex Bio, Inc. (NASDAQ:TRXB) Stock Has Consensus Target Price of $29.67 According to Brokerages

TRex Bio, Inc. (NASDAQ:TRXB) has received a consensus rating of “Buy” from the six research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $29.67.

A number of equities research analysts have recently commented on TRXB shares. Wedbush initiated coverage on shares of TRex Bio in a report on Monday, November 2nd. They set an “outperform” rating and a $30.00 price target for the company. Stifel Nicolaus initiated coverage on shares of TRex Bio in a research note on Tuesday, November 3rd. They set a “buy” rating and a $39.00 price objective on the stock. Zacks Research assumed coverage on shares of TRex Bio in a research report on Tuesday, November 3rd. They set a “hold” rating on the stock. Evercore began coverage on shares of TRex Bio in a research report on Tuesday, November 3rd. They set a “strong-buy” rating on the stock. Finally, Cantor Fitzgerald assumed coverage on TRex Bio in a report on Tuesday, November 3rd. They issued an “overweight” rating for the company.

Insider Transactions at TRex Bio

In other TRex Bio news, major shareholder Alexandria Venture Investments purchased 178,571 shares of the stock in a transaction on Tuesday, October 13th. The stock was bought at an average price of $14.00 per share, for a total transaction of $2,499,994.00. Following the acquisition, the insider directly owned 1,346,501 shares of the company’s stock, valued at $18,851,014. This represents a 15.29% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link.

TRex Bio Stock Performance

Shares of TRXB stock opened at $13.59 on Thursday. TRex Bio has a twelve month low of $12.50 and a twelve month high of $16.56.

About TRex Bio

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.